Immune Checkpoint Inhibitor-induced Fanconi Syndrome

Immune checkpoint inhibitors (ICI) have been approved by the Food and Drug Administration (FDA) for use in many solid tumors and hematological malignancies. Immune-related adverse events (irAEs) are potential side effects that can arise during or after treatment with ICI therapy. We describe a case...

Descripción completa

Detalles Bibliográficos
Autores principales: Farid, Saira, Latif, Hira, Nilubol, Chanigan, Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233517/
https://www.ncbi.nlm.nih.gov/pubmed/32431966
http://dx.doi.org/10.7759/cureus.7686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233517/
https://www.ncbi.nlm.nih.gov/pubmed/32431966
http://dx.doi.org/10.7759/cureus.7686

Ejemplares similares